<DOC>
	<DOC>NCT02172482</DOC>
	<brief_summary>As part of the post-marketing surveillance, information is to be gathered regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice</brief_summary>
	<brief_title>Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Men and women aged at least 40 years presenting with the symptoms of COPD Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>